Loading
A phase 3 trial of Olverembatinib run by Ascentage Pharma Group Inc., now recruiting.
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) is a phase 3 interventional study registered as NCT06051409 by Ascentage Pharma Group Inc., with 350 participants planned, started 2023-08-31. Conditions listed: Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive. No results are recorded here; the registry entry is the source.
Shares Olverembatinib, Ascentage Pharma, Small-molecule kinase inhibitors.
Shares Olverembatinib, Ascentage Pharma, Small-molecule kinase inhibitors.
Shares Olverembatinib, Ascentage Pharma.
Shares Olverembatinib, Ascentage Pharma, Acute lymphoblastic leukaemia.